Price T Rowe Associates Inc Esperion Therapeutics, Inc. Transaction History

Price T Rowe Associates Inc

$935 Billion
Q3 2025

A detailed history of Price T Rowe Associates Inc transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 152,890 shares of ESPR stock, worth $443,381. This represents 0.0% of its overall portfolio holdings.

Number of Shares

152,890

Previous 134,514 13.66%

Holding current value

$443,381

Previous $132,000 207.58%

% of portfolio

0.0%

Previous 0.0%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$0.98 - $2.84 $18,008 - $52,187	18,376 Added 13.66%	152,890 $406,000
Q2 2025 Aug 14, 2025	BUY	$0.73 - $1.41 $6,541 - $12,635	8,961 Added 7.14%	134,514 $132,000
Q1 2025 May 14, 2025	BUY	$1.44 - $2.34 $2,386 - $3,877	1,657 Added 1.34%	125,553 $181,000
Q4 2024 Feb 14, 2025	BUY	$1.61 - $3.83 $26,410 - $62,827	16,404 Added 15.26%	123,896 $273,000
Q2 2024 Aug 14, 2024	BUY	$1.84 - $3.24 $132,649 - $233,578	72,092 Added 203.65%	107,492 $239,000

Q3 2023 Nov 14, 2023	BUY	$0.96 - $1.79 $19,008 - $35,442	19,800 Added 126.92%	35,400 $35,000
Q2 2023 Aug 14, 2023	SELL	$1.2 - $1.76 $16,996 - $24,928	-14,164 Reduced 47.59%	15,600 $22,000
Q1 2023 May 15, 2023	BUY	$1.46 - $7.3 $1,638 - $8,190	1,122 Added 3.92%	29,764 $48,000
Q4 2022 Feb 14, 2023	BUY	$5.09 - $8.5 $7,202 - $12,027	1,415 Added 5.2%	28,642 $178,000
Q3 2022 Nov 14, 2022	BUY	$5.45 - $8.13 $51,273 - $76,487	9,408 Added 52.8%	27,227 $183,000
Q2 2022 Aug 15, 2022	BUY	$4.77 - $6.67 $3,472 - $4,855	728 Added 4.26%	17,819 $113,000
Q1 2022 May 16, 2022	BUY	$3.34 - $5.56 $57,083 - $95,025	17,091 New	17,091 $79,000
Q4 2021 Feb 14, 2022	SELL	$4.81 - $11.92 $108,330 - $268,462	-22,522 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$11.34 - $21.37 $56,700 - $106,850	5,000 Added 28.54%	22,522 $271,000
Q2 2021 Aug 16, 2021	BUY	$19.4 - $28.71 $9,312 - $13,780	480 Added 2.82%	17,522 $371,000
Q1 2021 May 17, 2021	BUY	$25.12 - $36.89 $175,237 - $257,344	6,976 Added 69.3%	17,042 $478,000
Q4 2020 Feb 16, 2021	BUY	$24.2 - $35.76 $243,597 - $359,960	10,066 New	10,066 $262,000

Others Institutions Holding ESPR

# of Institutions

215

Shares Held

114M

Call Options Held

643K

Put Options Held

769K

View Full List

About Esperion Therapeutics, Inc.

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $193M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

More about ESPR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Account

Price T Rowe Associates Inc Esperion Therapeutics, Inc. Transaction History